美国、亚太和中国肝癌共识比较

樊嘉; 潘奇; 史颖弘

美国、亚太和中国肝癌共识比较

复旦大学附属中山医院肝外科肝癌研究所

详细信息

中图分类号: R735.7
计量
- 文章访问数: 3816
- HTML全文浏览量: 20
- PDF下载量: 1677
- 被引次数: 0
出版历程
- 收稿日期: 2011-01-18
- 出版日期: 2011-04-20

Comparison of diagnostic and treatment algorithm of America, Asia-Pacific and China for hepatocellular carcinoma

摘要

摘要: 原发性肝癌是临床上常见的恶性肿瘤,规范化诊疗在国内外均引起高度关注,美国肝病研究学会、亚太肝脏研究学会及中国抗癌协会肝癌专业委员会和临床肿瘤学协作专业委员会以及中华医学会肝病学会肝癌学组均制定了原发性肝癌规范化诊治专家共识或诊治指南,本文通过对美国、亚太和中国肝癌共识进行比较,分析其对肝癌诊治临床实践的参考价值和指导意义。
- 肝肿瘤 /
- 诊疗准则
Abstract: Primary hepatocellular carcinoma is the one of most common cancer worldwide, and diagnostic and treatment algorithms varies in different regions.American, Asian Pacific, and Chinese associations for the study of the liver have published their hepatocellular carcinoma expert consensus independently.In this article, we will analyze the difference and significance of the consensus by comparing of those three algorithms.
- liver neoplasms /
- practice guideline

HTML全文

参考文献(9)

[1]Tang ZY, Ye SL, Liu YK, et al.A decade's studies on metastasisof hepatocellular carcinoma[J].J Cancer Res Clin Oncol, 2004, 130 (4) :187-196.

[2]Bruix J, Sherman M.Management of hepatocellular carcinoma:AnUpdate.Practice Guidelines Committee, American Association forthe Study of Liver Diseases[DB/OL].2010, http://www.aasld.org.

[3]Bruix J, Sherman M.Management of hepatocellular carcinoma.Practice guidelines committee, American association for the studyof liver diseases[J].Hepatology, 2005, 42 (5) :1208-1236.

[4]Omata M, Lesmana LA, Tateishi R, et al.Asian pacific associationfor the study of the liver consensus recommendations onhepatocellular carcinoma[J].Hepatol Int, 2010, 4 (2) :439-474.

[5]中国抗癌协会肝癌专业委员会, 中国抗癌协会临床肿瘤学协作委员会, 中华医学会肝病学分会肝癌学组.原发性肝癌规范化诊治专家共识[J].临床肿瘤学杂志, 2009, 14 (3) :259-269

[6]Breedis C, Young G.The blood supply of neoplasm in theliver[J].Am J Pathol, 1954, 30 (5) :969-977.

[7]樊嘉, 周俭, 徐泱, 等.肝癌肝移植适应证的选择:上海复旦标准[J].中华医学杂志, 2006, 86 (18) :1227-1231.

[8] Zheng SS, Xu X, Wu J, et al.Liver transplantation forhepatocellular carcinoma:Hangzhou experiences[J].Transplantation, 2008, 85 (12) :1726-1732.

[9]Printz C.Clinical trials of note.Sorafenib as adjuvanttreatment in the prevention of disease recurrence in patientswith hepatocellular carcinoma (HCC) (STORM) [J].Cancer, 2009, 115 (20) :4646.

施引文献

资源附件(0)

访问统计